The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease

Current Opinion in Investigational Drugs

Volumn 9, Issue 10, 2008, Pages 1084-1088

  Gentile, C L ^a   Pagliassotti, M J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Insulin resistance; Nonalcoholic fatty liver disease; Obesity; Steatosis; Unfolded protein response

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CCAAT BINDING FACTOR; CHAPERONE; CYTOKINE; GLUCOSE REGULATED PROTEIN 78; TAUROURSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID;

DRUG RESEARCH; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMAN; INSULIN RESISTANCE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PROTEIN ASSEMBLY; PROTEIN TARGETING; REVIEW;

ANIMALS; DIABETES MELLITUS; ENDOPLASMIC RETICULUM; FATTY LIVER; HUMANS; MOLECULAR CHAPERONES; OBESITY;

EID: 53049097438     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Calamita G, Portincasa P: Present and future therapeutic strategies for nonalcoholic fatty liver disease. Expert Opin Ther Targets (2007) 11(9):1231-1249.
2. Clark JM, Diehl A: Nonalcoholic fatty liver disease: An under-recognized cause of cryptogenic cirrhosis. J Am Med Assoc (2003) 289(22):3000-3004.
3. Wieckowska A, McCullough AJ, Feldstein AE: Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future. Hepatology (2007) 46(2):582-589.
4. Papandreou D, Rousso I, Mavromichalis I: Update on nonalcoholic fatty liver disease in children. Clin Nutr (2007) 26(4):409-415.
5. Day CP, James O: Steatohepatitis: A tale of two 'hits'? Gastroenterology (1998) 114(4):842-845.
6. Gill HK, Wu GY: Nonalcoholic fatty liver disease and the metabolic syndrome: Effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J Gastroenterol (2006) 12(3):345-353.
7. Pahl HL: Signal transduction from the endoplasmic reticulum to the cell nucleus. Physiol Rev (1999) 79(3):683-701.
8. Kaufman RJ: Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls. Genes Dev (1999) 13(10):1211-1233. •• An exceptional review of the UPR.
9. Kaufman RJ: Orchestrating the unfolded protein response in health and disease. J Clin Invest (2002) 110(10):1389-1398.
10. Rutkowski DT, Kaufman RJ: A trip to the ER: Coping with stress. Trends Cell Biol (2004) 14(1):20-28.
11. -/- mice reveals a role for translational control in secretory cell survival. Mol Cell (2001) 7(6):1153-1163.
12. Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P, Saunders T, Bonner-Weir S, Kaufman RJ: Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell (2001) 7(6):1165-1176. •• Among the first papers to demonstrate a link between the UPR and glucose homeostasis.
13. Kim SH, Hwang CI, Park WY, Lee JH, Song YS: GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. Carcinogenesis (2006) 27(10):1961-1969.
14. Oyadomari S, Mori M: Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ (2004) 11(4):381-389.
15. Oyadomari S, Koizumi A, Takeda K, Gotoh T, Akira S, Araki E, Mori M: Targeted disruption of the CHOP gene delays endoplasmic reticulum-stress mediated diabetes. J Clin Invest (2002) 109(4):525-532.
16. Shi Y, Taylor SI, Tan S-L, Sonenberg N: When translation meets metabolism: Multiple links to diabetes. Endocr Rev (2003) 24(1):91-101.
17. Zhao L, Ackerman SL: Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol (2006) 18(4):444-452.
18. Wang D, Wei Y, Schmoll D, Maclean KN, Pagliassotti MJ: Endoplasmic reticulum stress increases glucose-6-phosphatase and glucose cycling in liver cells. Endocrinology (2006) 147(1): 350-358.
19. Ozcan U, Cao Q, Yilmaz E, Lee A-H, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün CZ, Glimcher LH, Hotamisligil GS: Endoplasmic reticulum stress links obesity, insulin action and type 2 diabetes. Science (2004) 306(5695):457-461. •• This paper was among the first to document the presence of ER stress in obesity and the participation of the UPR in the regulation of insulin action.
20. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G: Hepatic steatosis in obese patients: Clinical aspects and prognostic significance. Obes Rev (2004) 5(1):27-42.
21. Samuel VT, Liu Z-X, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI: Mechanism of hepatic insulin resistance in nonalcoholic fatty liver disease. J Biol Chem (2004) 279(31):32345-32353.
22. Nakatani Y, Kaneto H, Kawamori D, Yoshiuchi K, Hatazaki M, Matsuoka TA, Ozawa K, Ogawa S, Hori M, Yamasaki Y, Matsuhisa M: Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem (2005) 280(1):847-851.
23. Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, Sanyal AJ: Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2008) 134(2):568-576. •• The only documented report of ER stress in humans with NAFLD to date.
24. Das SK, Chu WS, Mondal AK, Sharma NK, Kern PA, Rasouli N, Elbein SC: Endoplasmic reticulum stress response is not reduced with pioglitazone in human adipose tissue or human hepatocyte HepG2 cell lines. Am Diabetes Assoc (2008) 68:Abs 1931-P.
25. Sriburi R, Jackowski S, Mori K, Brewer JW: XBP1: A link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J Cell Biol (2004) 167(1):35-41. •• This paper was among the first to document the role of XBP1 in lipid biosynthesis.
26. Lee A-H, Scapa EF, Cohen DE, Glimcher LH: Regulation of hepatic lipogenesis by the transcription factor XBP1. Science (2008) 320(5882):1492-1496. •• This paper demonstrated that deletion of XBP1 in the liver resulted in hypocholesterolemia and hypotriglyceridemia, secondary to decreased production of lipids by the liver.
27. Oyadomari S, Harding H, Zhang Y, Oyadomari M, Ron D: Dephosphorylation of translation initiation factor 2α enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab (2008) 7(6):520-532.
28. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, Sweeney M, Rong JX, Kuriakose G, Fisher EA, Marks AR et al: The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol (2003) 5(9):781-792.
29. Yang L, Jhaveri R, Huang J, Qi Y, Diehl AM: Endoplasmic reticulum stress, hepatocytes CD1d and NK T-cell abnormalities in murine fatty livers. Lab Invest (2007) 87(9):927-937.
30. Kharroubi I, Ladriere L, Cardozo AK, Dogusan Z, Cnop M, Eizirik DL: Free fatty acids and cytokines induce pancreatic β-cell apoptosis by different mechanisms: Role of nuclear factor-κB and endoplasmic reticulum stress. Endocrinology (2004) 145(11):5087-5096.
31. Borradaile NM, Han X, Harp JD, Gale SE, Ory DS, Schaffer JE: Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res (2006) 47(12):2726-2737. •• An important study that demonstrated the sensitivity of the ER to saturated fatty acids.
32. Wang D, Wei Y, Pagliassotti MJ: Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology (2006) 147(2):943-951.
33. Wei Y, Wang D, Topczewski F, Pagliassotti MJ: Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab (2006) 291(2):E275-E281.
34. Ota T, Gayet C, Ginsberg HN: Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest (2008) 118(1):316-332.
35. Welch WJ, Brown CR: Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones (1996) 1(2):109-115.
36. Kolter T, Wendeler M: Chemical chaperones - a new concept in drug research. Chembiochem (2003) 4(4):260-264.
37. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS: Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science (2006) 313(5790):1137-1140. •• This study demonstrated that chemical chaperones enhance the adaptive capacity of the ER and can act as potent antidiabetic agents with potential application in the treatment of type 2 diabetes and NAFLD.
38. Xie Q, Khaoustov VI, Chung CC, Sohn J, Krishnan B, Lewis DE, Yoffe B: Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology (2002) 36(3):592-601.
39. Loo TW, Clarke DM: Chemical and pharmacological chaperones as new therapeutic agents. Expert Rev Mol Med (2007) 9(16):1-18.
40. Wei H, Kim SJ, Zhang Z, Tsai PC, Wisniewski KE, Mukherjee AB: ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum Mol Genet (2008) 17(4):469-477.
41. 2+-, PKC-, and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol (2004) 286(6):G973-G982.
42. de Almeida SF, Picarote G, Fleming JV, Carmo-Fonseca M, Azevedo JE, de Sousa M: Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J Biol Chem (2007) 282(38):27905-27912.
43. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ: Oral sodium phenylbutyrate therapy in homozygous β thalassemia: A clinical trial. Blood (1995) 85(1):43-49.
44. Maestri NE, Brusilow SW, Clissold DB, Bassett SS: Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med (1996) 335(12):855-859.
45. Kaplan MM, Gershwin ME: Primary biliary cirrhosis. N Engl J Med (2005) 353(12):1261-1273.
46. Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE: Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology (1999) 29(1):39-43.
47. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology (1996) 23(6):1464-1467.
48. Santos VN, Lanzoni VP, Szejnfeld J, Shigueoka D, Parise ER: A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. Braz J Med Biol Res (2003) 36(6):723-729.
49. Ersoz G, Gunsar F, Karasu Z, Akay S, Batur Y, Akarca US: Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol (2005) 16(3):124-128.
50. Méndez-Sánchez N, González V, Chávez-Tapia N, Ramos MH, Uribe M: Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol (2004) 3(3):108-112.
51. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology (2004) 39(3):770-778.